



IN THE CLAIMS

1 – 2. (Canceled)

3. (Currently amended) A pharmaceutical composition for the treatment of inflammation consisting essentially of the compound of formula (IA)



and meloxicam of formula



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, wherein the composition has a weight ratio of formula (IA) to meloxicam of 1:20.

4 – 8. (Canceled)

9. (Withdrawn – previously presented) A method for the prevention or treatment of a disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus; and juvenile arthritis, asthma, hay fever, atopic dermatitis, rhinitis, bronchitis, COPD, cystic fibrosis, psoriasis, scleroderma, morbus bechterew, sarcoidosis, tumor metastasis, morbus crohn, colitis ulcerosa, IBD, multiple sclerosis, arteriosclerosis, arteritis, myocardial infarction, stroke, coronary heart disease which method comprises administration of effective amounts of a composition according to claim 2 to a patient in need thereof in a combined form, or separately or separately and sequentially.


10. (Withdrawn – previously presented) A method according to claim 9 for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.

11. (Withdrawn – previously presented) A method for the manufacture of a medicament for the prevention or treatment of disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, asthma, bronchitis, COPD and cystic fibrosis comprising mixing a LTB₄ antagonist according to claim 2 and meloxicam in a combined form.

12. (Withdrawn – previously presented) The method according to claim 11 wherein the medicament for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.

13. (Currently amended) A pharmaceutical kit for the treatment of inflammation consisting essentially of two separate unit dosage forms (A) and (B):

(A) comprises a composition containing a LTB₄ antagonist, of formula (IA)



or a tautomer, a pharmaceutically acceptable salt or solvate thereof; and

(B) comprises meloxicam, and optionally a pharmaceutically acceptable carrier or excipient,

wherein the composition has a weight ratio of formula (IA) to meloxicam of 1:20.

14. (Previously presented) A pharmaceutical formulation according to claim 3 which is suitable for oral, intravascular, intraperitoneal, subcutaneous, intramuscular or topical administration.

15. (Currently amended) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 1-250 mg of formula (IA) and 20-5000 mg of meloxicam ~~the weight ratio of LTB₄ antagonist to meloxicam ranges from 1:10 up to 1:30.~~

16. (Currently amended) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 1-200 mg of formula (IA) and 20-4000 mg of meloxicam ~~1 to 5,000 milligrams of the combined active ingredients.~~

17. (Previously presented) A pharmaceutical formulation according to claim 3 wherein the pharmaceutically acceptable carrier or excipient is a carbohydrate.

18. (Currently amended) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 1-150 mg of formula (IA) and 20-3000 mg meloxicam ~~2-16 mg/kg meloxicam and 0.1-0.8 mg/kg formula IA, wherein the weight ratio of formula IA to meloxicam is 1:20.~~